Search details
1.
The prognostic value of radiomic features in liver-limited metastatic colorectal cancer patients from the TRIBE2 study.
Future Oncol
; 19(23): 1601-1611, 2023 Jul.
Article
in English
| MEDLINE | ID: mdl-37577810
2.
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
Lancet Oncol
; 21(4): 497-507, 2020 04.
Article
in English
| MEDLINE | ID: mdl-32164906
3.
Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer.
Br J Cancer
; 115(7): 789-96, 2016 09 27.
Article
in English
| MEDLINE | ID: mdl-27599039
4.
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
Lancet Oncol
; 16(13): 1306-15, 2015 Oct.
Article
in English
| MEDLINE | ID: mdl-26338525
5.
Baseline Cytokine Profile Identifies a Favorable Outcome in a Subgroup of Colorectal Cancer Patients Treated with Regorafenib.
Vaccines (Basel)
; 11(2)2023 Feb 02.
Article
in English
| MEDLINE | ID: mdl-36851213
6.
Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by the GONO Foundation.
J Clin Oncol
; 41(34): 5263-5273, 2023 Dec 01.
Article
in English
| MEDLINE | ID: mdl-37535876
7.
Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer.
Br J Cancer
; 115(9): e16, 2016 10 25.
Article
in English
| MEDLINE | ID: mdl-27727233
8.
Survival prediction and frequency of anticancer treatment in cancer patients hospitalized due to acute conditions. Role of clinical parameters and PaP score.
Support Care Cancer
; 19(11): 1823-30, 2011 Nov.
Article
in English
| MEDLINE | ID: mdl-21560032
9.
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
Lancet Oncol
; 11(9): 845-52, 2010 Sep.
Article
in English
| MEDLINE | ID: mdl-20702138
10.
Unusual Fatal Outcome Following Administration of a Combination of anti-PD1 and anti-CTLA4 in Metastatic Renal Cell Carcinoma: Liver Toxicity Case Report and a Literature Review.
Eur J Case Rep Intern Med
; 8(7): 002639, 2021.
Article
in English
| MEDLINE | ID: mdl-34268267
11.
Cytokine Profiling of End Stage Cancer Patients Treated with Immunotherapy.
Vaccines (Basel)
; 9(3)2021 Mar 08.
Article
in English
| MEDLINE | ID: mdl-33800511
12.
Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study.
Eur J Cancer
; 153: 16-26, 2021 08.
Article
in English
| MEDLINE | ID: mdl-34126333
13.
TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study.
Cancers (Basel)
; 13(11)2021 Jun 07.
Article
in English
| MEDLINE | ID: mdl-34200267
14.
Circulating cytokines and outcome in metastatic colorectal cancer patients treated with regorafenib.
World J Gastrointest Oncol
; 12(3): 301-310, 2020 Mar 15.
Article
in English
| MEDLINE | ID: mdl-32206180
15.
Treating patients with cancer amidst the COVID-19 pandemic: experience of a regional hospital in the Piedmont region in northern Italy.
Tumori
; 106(5): 427-431, 2020 Oct.
Article
in English
| MEDLINE | ID: mdl-32703089
16.
Discontinuation of first-line bevacizumab in metastatic colorectal cancer: the BEAWARE Italian Observational Study.
Tumori
; 105(3): 243-252, 2019 Jun.
Article
in English
| MEDLINE | ID: mdl-30857495
17.
Italian survey on cetuximab-based therapy of elderly patients with metastatic colorectal cancer.
Cancer Chemother Pharmacol
; 84(5): 1089-1096, 2019 Nov.
Article
in English
| MEDLINE | ID: mdl-31493178
18.
Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial.
Eur J Cancer
; 109: 175-182, 2019 03.
Article
in English
| MEDLINE | ID: mdl-30735919
19.
TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer.
ESMO Open
; 3(4): e000403, 2018.
Article
in English
| MEDLINE | ID: mdl-30018814
20.
Heterogeneity of colon cancer: from bench to bedside.
ESMO Open
; 2(3): e000218, 2017.
Article
in English
| MEDLINE | ID: mdl-29209524